Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

Rottapharm Biotech: POC in osteoarthritis pain

Results of the proof-of-concept trial suggest the selective imidazoline-2 (I2) receptor agonist CR4056 could be an alternative to the...

Researchers find new indication for cancer drug

Julie Gavard and colleagues at the University of Nantes identified a new druggable target against glioblastoma, the most common and lethal type of...

ADC Therapeutics set to go public

The number of shares to be offered and the price range for the proposed offering have still to be determined. Despite an internal review conducted...

MS: Polpharma joins forces with Sandoz

Natalizumab, which is currently being marketed by Biogen, is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is a...

Evotec and Celmatix enter strategic partnership

Under the terms of the strategic R&D collaboration, Celmatix Inc. (New York) will utilise its proprietary multi-omics Reproductive Atlas platform...

Sherlock Bioscience and Mologic enter partnership

Mologic said it will invest a part of an expansion to its $4.9m grant from the Bill and Melinda-Gates Foundation to finance access to Sherlock's...

BASF broadens biotech business by Isobionics acquisition

The acquisition of Isobionics BV (Geleen, The Netherlands) gives the the German world chemistry leader a foothold in the growing US$20.75bn market...